作者
Katharina Seystahl, Veit Stoecklein, Ulrich Schüller, Elisabeth Rushing, Guillaume Nicolas, Niklaus Schäfer, Harun Ilhan, Athina Pangalu, Michael Weller, Jörg-Christian Tonn, Michael Sommerauer, Nathalie L Albert
发表日期
2016/11/1
期刊
Neuro-oncology
卷号
18
期号
11
页码范围
1538-1547
出版商
Oxford University Press
简介
Background
The prognosis of patients with progressive meningioma after failure of surgery and radiotherapy is poor.
Methods
We retrospectively evaluated the safety and efficacy of somatostatin-receptor (SSTR)-targeted radionuclide therapy (177Lu-DOTATATE [n = 16], 90Y-DOTATOC [n = 3], or both [n = 1]) in patients with progressive, treatment-refractory meningiomas (5 World Health Organization [WHO] grade I, 7 WHO grade II, 8 WHO grade III) and in part multifocal disease (17 of 20 patients).
Results
SSTR radionuclide treatment (median of 3 treatment cycles, median administered dose/cycle 7400 MBq) led to a disease stabilization in 10 of 20 patients for a median time of 17 months. Stratification according to WHO grade showed a median progression-free survival (PFS) of 32.2 months for grade I tumors, 7.2 for grade II, and 2.1 for grade III. PFS at 6 …
学术搜索中的文章
K Seystahl, V Stoecklein, U Schüller, E Rushing… - Neuro-oncology, 2016